Skip to main content
Top of the Page

SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.

Learn more »

SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies.

Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.

Join Now

The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. The twelfth annual meeting of the Society of Hematologic Oncology (SOHO 2024) is scheduled for September 4-7, 2024 at the GRB Convention Center in Houston, Texas. As a hybrid event, SOHO 2024 offers in-person, virtual and on-demand participation.

Register Now
  • 8,186 members strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:
  • Instant connections to our SOHO Community of nearly 8,000 members
  • Access to a comprehensive Resource Center that includes slides, publications, abstracts, videos & more
  • Connection to our SOHO DocMatter Community for hematologic oncology discussions and education
  • Free online access to our official journal, ‘Clinical Lymphoma Myeloma and Leukemia
  • Free online and print subscription (US members) to our news publication, 'Blood Cancers Today'
  • Significant member-only discounts on meetings and events
  • Early member-only registration and housing opportunities
  • ... and much more!

Ambassador Program

The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!

Latest News

Risk of Bleeding Events in Patients With CLL Receiving BTKis

The incidence of bleeding events in patients with CLL receiving BTKis is 26.6 per 100 patients per year, according to a study presented at the 2024 American Society of Clinical Oncology Annual Meeting.

Analysis Shows MPN Depend on JAK Mutation for Persistence

MPN depend on mutated JAK signaling, and targeting the mutations suppressed disease features and improved overall survival.

Pelabresib With Ruxolitinib in Myelofibrosis

Pelabresib plus ruxolitinib improved spleen and symptom responses in JAKi-naïve patients with myelofibrosis.

FDA Approves Imetelstat for Patients With Lower-Risk MDS With Transfusion-Dependent Anemia

The approval was based on efficacy and safety results of the randomized, placebo-controlled IMerge study.

Luspatercept Improves Anemia Metrics Across Myelofibrosis Cohorts

Treatment with luspatercept improved transfusion burden and anemia across four cohorts of patients with myelofibrosis.

The HemOnc Pulse Live Unanswered Questions in Aggressive Non-Hodgkin Lymphoma

An expert panel convened at the "HemOnc Pulse" Live meeting in Chicago explores unanswered questions in DLBCL management.

The HemOnc Pulse Live What Are the Unanswered Questions in ALL

The panel discussed ALL treatment, associated toxicities, and the possibility of a chemotherapy-free approach.

"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world"
–Prof. Dieter Hoelzer, founding member
Back to Top